Brokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $14.00

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, one has issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $14.00.

Several analysts have recently issued reports on the company. Noble Financial raised NeuroSense Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of NeuroSense Therapeutics in a research report on Friday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research report on Thursday. Finally, Zacks Research upgraded shares of NeuroSense Therapeutics to a “hold” rating in a research report on Wednesday, October 15th.

NeuroSense Therapeutics Trading Up 5.6%

Shares of NRSN stock opened at $1.04 on Tuesday. NeuroSense Therapeutics has a 1 year low of $0.80 and a 1 year high of $2.60. The stock has a 50 day simple moving average of $1.16 and a 200 day simple moving average of $1.46.

Hedge Funds Weigh In On NeuroSense Therapeutics

A number of institutional investors have recently modified their holdings of the business. Two Sigma Investments LP acquired a new stake in NeuroSense Therapeutics in the third quarter valued at about $26,000. Jane Street Group LLC acquired a new stake in shares of NeuroSense Therapeutics in the 2nd quarter valued at approximately $54,000. Finally, Squarepoint Ops LLC grew its holdings in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares during the last quarter. Institutional investors and hedge funds own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.